行经皮冠状动脉介入治疗的冠心病患者实施瑞舒伐他汀联合替格瑞洛治疗的效果
|
摘要
目的分析行经皮冠状动脉介入治疗的冠心病患者实施瑞舒伐他汀联合替格瑞洛治疗的效果。方法选取2017年4月～2018年4月我院收治的80例行经皮冠状动脉介入治疗的冠心病患者作为研究对象,按照电脑随机方法将其分为观察组(40例)与对照组(40例)。观察组患者采用瑞舒伐他汀联合替格瑞洛治疗,对照组患者采用常规治疗方法。比较两组患者的不良心血管事件总发生率、治疗总有效率、纤维蛋白原(Fbg)、血小板聚集率(PAgT)、凝血酶原时间(PT)、住院时间及症状缓解时间。结果观察组患者的不良心血管事件总发生率为5.00%,显著低于对照组的25.00%,差异有统计学意义(P<0.05)。观察组患者的治疗总有效率为87.50%,高于对照组的67.50%,差异有统计学意义(P<0.05)。两组患者治疗前的Fbg、PAgT、PT比较,差异无统计学意义(P>0.05);两组患者治疗后的Fbg、PagT均低于治疗前,PT短于治疗前,差异有统计学意义(P<0.05);观察组患者治疗后的Fbg、PAgT均低于对照组,PT短于对照组,差异有统计学意义(P<0.05)。观察组患者的住院时间、症状缓解时间均短于对照组,差异有统计学意义(P<0.05)。结论采用瑞舒伐他汀联合替格瑞洛治疗行经皮冠状动脉介入冠心病患者的效果显著,值得临床推广应用。
Objective To analyze the effect of Rosuvastatin combined with Ticagrelor in the treatment of patients with coronary heart disease undergoing percutaneous coronary intervention.Methods Eighty patients with coronary heart disease who underwent percutaneous coronary intervention from April 2017 to April 2018 in our hospital were selected as research objects.The patients were divided into observation group(40 cases) and control group(40 cases) according to the computer random method.In the observation group,Rosuvastatin combined with Ticagrelor was adopted,and in the control group,conventional treatment was used.The total incidence rate of adverse cardiovascular events,total effective rate of treatment,fibrinogen(Fbg),platelet aggregation test(PAgT),prothrombin time(PT),hospitalization time,and symptom relief time were compared between the two groups.Results The total incidence rate of adverse cardiovascular events was 5.00% in the observation group,which was significantly lower than that in the control group accounting for 25.00%,and the difference was statistically significant(P<0.05).The total effective rate of treatment in the observation group was 87.50%,which was significantly higher than that in the control group accounting for 67.50%,and the difference was statistically significant(P<0.05).There were no significant differences in Fbg,PAgT and PT between the two groups before treatment(P>0.05).The Fbg and PagT after treatment in the two groups were lower than those before treatment,the PT was shorter than that before treatment,and the differences were statistically significant(P<0.05).The Fbg and PagT after treatment in the observation group were lower than those in the control group,the PT was shorter than that in the control group,and the differences were statistically significant(P<0.05).The hospitalization time and symptom relief time in the observation group were shorter than those in the control group,and the differences were statistically significant(P<0.05).Conclusion The application of Rosuvastatin combined with Ticagrelor can obtain a remarkable effect in the treatment of patients with coronary heart disease undergoing percutaneous coronary intervention and it is worthy of clinical application and promotion.
Objective To analyze the effect of Rosuvastatin combined with Ticagrelor in the treatment of patients with coronary heart disease undergoing percutaneous coronary intervention.Methods Eighty patients with coronary heart disease who underwent percutaneous coronary intervention from April 2017 to April 2018 in our hospital were selected as research objects.The patients were divided into observation group(40 cases) and control group(40 cases) according to the computer random method.In the observation group,Rosuvastatin combined with Ticagrelor was adopted,and in the control group,conventional treatment was used.The total incidence rate of adverse cardiovascular events,total effective rate of treatment,fibrinogen(Fbg),platelet aggregation test(PAgT),prothrombin time(PT),hospitalization time,and symptom relief time were compared between the two groups.Results The total incidence rate of adverse cardiovascular events was 5.00% in the observation group,which was significantly lower than that in the control group accounting for 25.00%,and the difference was statistically significant(P<0.05).The total effective rate of treatment in the observation group was 87.50%,which was significantly higher than that in the control group accounting for 67.50%,and the difference was statistically significant(P<0.05).There were no significant differences in Fbg,PAgT and PT between the two groups before treatment(P>0.05).The Fbg and PagT after treatment in the two groups were lower than those before treatment,the PT was shorter than that before treatment,and the differences were statistically significant(P<0.05).The Fbg and PagT after treatment in the observation group were lower than those in the control group,the PT was shorter than that in the control group,and the differences were statistically significant(P<0.05).The hospitalization time and symptom relief time in the observation group were shorter than those in the control group,and the differences were statistically significant(P<0.05).Conclusion The application of Rosuvastatin combined with Ticagrelor can obtain a remarkable effect in the treatment of patients with coronary heart disease undergoing percutaneous coronary intervention and it is worthy of clinical application and promotion.
引文
[1]杨文,刘洁云,秦雷,等.瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效对比研究[J].中国全科医学,2013,16(6):621-623.
[2]陈翀昊,王广燕,苏衡,等.瑞舒伐他汀与阿托伐他汀对早发冠心病急性心肌梗死患者的近期疗效[J].中国临床药理学杂志,2013,29(2):126-128.
[3]刘兵,杨春梅,张立,等.阿托伐他汀联合曲美他嗪治疗冠心病的疗效[J].中国老年学杂志,2013,33(23):5791-5792.
[4]王学胜,张学平,陈慧,等.稳心颗粒联合美托洛尔治疗老年人冠心病心律失常的临床疗效观察[J].中华老年医学杂志,2013,32(11):1159-1160.
[5]冯春艳,苏东辉,于军.替格瑞洛对冠心病患者经皮冠状动脉介入治疗术后冠脉微循环功能的影响[J].血栓与止血学,2016,22(5):507-510.
[6]刘新兵,冯六六,黄红漫,等.无创正压通气治疗对冠心病合并阻塞性睡眠呼吸暂停低通气综合征患者心律失常影响研究[J].中国循环杂志,2014,29(1):21-25.
[7]许加素,彭晓琳,李洪林,等.葛根素注射液联合胺碘酮治疗冠心病患者PCI术后并发心律失常的疗效分析[J].中国药房,2016,27(36):5079-5081.
[8]岳豪祥,钱丽华,王文欣,等.瑞舒伐他汀治疗冠心病患者疗效观察及对患者凝血、血液流变学、血脂、细胞因子水平的影响[J].安徽医药,2016,20(4):772-775.
[9]丁晓虎,李彩云,丁峰.依折麦布联合瑞舒伐他汀治疗冠心病患者血脂异常的疗效与安全性的Meta分析[J].江苏医药,2016,42(9):1042-1044.
[10]刘向阳,唐良秋,李爱华.冠心病患者心率变异与氨基末端脑钠肽前体的相关性研究[J].现代医院,2017,17(2):227-229.
[11]钟海.阿司匹林与氯吡格雷治疗老年冠心病患者的临床疗效比较[J].中国民康医学,2016,28(10):57-58.
[12]欧番文,滕璇,梁牧.氯吡格雷联合阿司匹林治疗冠心病患者经皮冠状动脉介入治疗术后抗血小板疗效影响[J].吉林医学,2016,37(11):2744-2746.
[13]王转前.曲美他嗪、阿托伐他汀联合治疗老年冠心病患者的疗效分析[J].中西医结合心血管病电子杂志,2016,4(14):29-30.
[14]陈云江,龚艳春.氯吡格雷治疗冠心病患者的临床疗效观察[J].心脑血管病防治,2016,16(2):122-123.
[15]段艳蕊,孙建威.中西医结合治疗老年冠心病患者的临床疗效观察及对生活质量的影响[J].中华保健医学杂志,2016,18(3):238-239.
[16]黄强,李明琰.替格瑞洛在冠脉介入治疗后的治疗效果及安全性临床观察[J].中国医药科学,2017,7(12):39-41.
[17]孙阿林,庞军涛,马长虹,等.应用血栓弹力图评估不同抗血小板药物在老年冠心病患者中的疗效及对策[J].中国医药导报,2016,13(32):69-72.
[18]赵满,冷玉萍,贾玉娜,等.瑞舒伐他汀治疗冠心病急性心肌梗死的效果[J].中国医药导报,2016,13(18):157-160.
[19]叶健英,黄玉萍,杨瑞红,等.瑞舒伐他汀联合依那普利治疗原发性高血压合并冠心病的疗效观察[J].现代医院,2018,18(3):408-410.
[2]陈翀昊,王广燕,苏衡,等.瑞舒伐他汀与阿托伐他汀对早发冠心病急性心肌梗死患者的近期疗效[J].中国临床药理学杂志,2013,29(2):126-128.
[3]刘兵,杨春梅,张立,等.阿托伐他汀联合曲美他嗪治疗冠心病的疗效[J].中国老年学杂志,2013,33(23):5791-5792.
[4]王学胜,张学平,陈慧,等.稳心颗粒联合美托洛尔治疗老年人冠心病心律失常的临床疗效观察[J].中华老年医学杂志,2013,32(11):1159-1160.
[5]冯春艳,苏东辉,于军.替格瑞洛对冠心病患者经皮冠状动脉介入治疗术后冠脉微循环功能的影响[J].血栓与止血学,2016,22(5):507-510.
[6]刘新兵,冯六六,黄红漫,等.无创正压通气治疗对冠心病合并阻塞性睡眠呼吸暂停低通气综合征患者心律失常影响研究[J].中国循环杂志,2014,29(1):21-25.
[7]许加素,彭晓琳,李洪林,等.葛根素注射液联合胺碘酮治疗冠心病患者PCI术后并发心律失常的疗效分析[J].中国药房,2016,27(36):5079-5081.
[8]岳豪祥,钱丽华,王文欣,等.瑞舒伐他汀治疗冠心病患者疗效观察及对患者凝血、血液流变学、血脂、细胞因子水平的影响[J].安徽医药,2016,20(4):772-775.
[9]丁晓虎,李彩云,丁峰.依折麦布联合瑞舒伐他汀治疗冠心病患者血脂异常的疗效与安全性的Meta分析[J].江苏医药,2016,42(9):1042-1044.
[10]刘向阳,唐良秋,李爱华.冠心病患者心率变异与氨基末端脑钠肽前体的相关性研究[J].现代医院,2017,17(2):227-229.
[11]钟海.阿司匹林与氯吡格雷治疗老年冠心病患者的临床疗效比较[J].中国民康医学,2016,28(10):57-58.
[12]欧番文,滕璇,梁牧.氯吡格雷联合阿司匹林治疗冠心病患者经皮冠状动脉介入治疗术后抗血小板疗效影响[J].吉林医学,2016,37(11):2744-2746.
[13]王转前.曲美他嗪、阿托伐他汀联合治疗老年冠心病患者的疗效分析[J].中西医结合心血管病电子杂志,2016,4(14):29-30.
[14]陈云江,龚艳春.氯吡格雷治疗冠心病患者的临床疗效观察[J].心脑血管病防治,2016,16(2):122-123.
[15]段艳蕊,孙建威.中西医结合治疗老年冠心病患者的临床疗效观察及对生活质量的影响[J].中华保健医学杂志,2016,18(3):238-239.
[16]黄强,李明琰.替格瑞洛在冠脉介入治疗后的治疗效果及安全性临床观察[J].中国医药科学,2017,7(12):39-41.
[17]孙阿林,庞军涛,马长虹,等.应用血栓弹力图评估不同抗血小板药物在老年冠心病患者中的疗效及对策[J].中国医药导报,2016,13(32):69-72.
[18]赵满,冷玉萍,贾玉娜,等.瑞舒伐他汀治疗冠心病急性心肌梗死的效果[J].中国医药导报,2016,13(18):157-160.
[19]叶健英,黄玉萍,杨瑞红,等.瑞舒伐他汀联合依那普利治疗原发性高血压合并冠心病的疗效观察[J].现代医院,2018,18(3):408-410.